| No. |
Date |
Time |
Seminar Title |
Register |
| Keynote / Special Seminar |
| 3K-02 |
21 April (Tue.) |
11:00
|
12:00 |
Gateway to Japan: A Triple-Helix Platform for Global Biotech Innovators
Ms. Wakako Toga
Deputy Director
Research Institute and Strategic Planning Bureau
National Cancer Center (NCC) Japan］
［Japanese→English Translation］
|
 |
| 3K-03 |
21 April (Tue.) |
13:00
|
14:00 |
From Patient Centricity to Sustainable Growth: Kyowa Kirin’s Vision 2030 and Beyond: Our Growth Story
Abdul Mullick, Ph.D.
Representative Director, President and CEO
Kyowa Kirin Co., Ltd.
|
|
| 3K-05 |
21 April (Tue.) |
16:00
|
16:30 |
Perspectives on the Japan Pharmaceutical Market – Outlook to 2030
Mr . Alan Thomas
Senior Director
Japan Thought Leadership
IQVIA Solutions Japan
［English→Japanese Translation］
|
|
| 3K-07 |
22 April (Wed.) |
11:30
|
12:30 |
Annual Pharma R&D Review: The Current State of the Global Biopharma Pipeline
Mr. Ian Haydock
Editor-in-Chief, APAC
Citeline
Norstella
［English→Japanese Translation］
|
|
| 3K-08 |
22 April (Wed.) |
13:30
|
15:00 |
JPTA Seminar - Ensuring Stable API Supply
Organised by Japan Pharmaceutical Traders' Association
Supported by Italian Trade Agency, Trade Promotion Section, Embassy of Italy
Aschimfarma , Chemical Pharmaceutical Generic Association
The Japanese Pharmaceutical and Medical Device Act was revised in 2025, and preparations and considerations for its implementations are underway. To support this process, JPTA will host a seminar featuring Italian API manufacturers, focusing on their understanding of Japanese pharmaceutical regulations and their requests for improvements to facilitate business operations and ensure a stable supply of APIs.
［English→Japanese Translation］
Programme
Opening Remarks:
Mr. Ichiro Fujikawa, Chairperson, Japan Pharmaceutical Traders' Association
Presentation 1:
Characteristics of the Japanese Market and Challenges for Stable Supply from an API Manufacturer's Perspective
Mr. Fabio Pirola, LUSOCHIMICA S.p.A.
Presentation 2:
Regulatory Challenges in Supplying APIs to Japan, which Differs from European and American Pharmaceutical Systems: focus on GMP compliance, evolving regulatory landscape and harmonization
Ms. Annalisa Scali, TRIFARMA S.p.A.
Presentation 3:
Expectations for improvements to Japan’s pharmaceutical regulatory framework in relation to API exports
Ms. Eleonora Baioni, Indena S.p.A
Presentation 4:
Navigating Japan’s Evolving Pharmaceutical Regulatory Landscape – Global Manufacturer Perspectives
Mr. Daniele Oldani, ICROM S.r.l.
Closing Remarks:
Mr. Hiroshi Nakamura, Chairman, Legal Committee, Japan Pharmaceutical Traders' Association
|
|
| 3K-11 |
23 April (Thu.) |
09:30
|
10:30 |
Building a drug discovery ecosystem in Japan
|
|
| General Session |
| 3A-01 |
21 April (Tue.) |
10:30
|
11:30 |
Regulatory strategy for oversea expansion with case studies of Japanese companies
Mr. Jack Wong
CEO ＆ Founder
Asia Regulatory Professionals Association (ARPA)
［English→Japanese Translation］
|
|
| Biopharma / Regenerative Medicine Seminar |
| 3C-12 |
23 April (Thu.) |
10:00
|
11:30 |
【TIDES Collaboration Project】
Alternative Oligo Synthesis and the Future Therapeutic Oligonucleotide Landscape
Yogesh Sanghvi, Ph.D.,
President,
Rasayan, Inc., USA
*This seminar is a pre-recorded session.
|
|
| CDMO/CMO Seminar |
| 1A-13 |
23 April (Thu.) |
11:45
|
12:30 |
Controlling ADC Distribution Profiles under Formosa Labs ADC platform:
Through Site-Specific and Site-Selective Approaches
Mr. Timeus, Tzu-Chiao Kao
R&D director
R&D
Formosa Laboratories, Inc.
［English→Japanese Translation］
|
|
| Overseas seminar |
| 3C-09 |
22 April (Wed.) |
13:00
|
14:20 |
Your global strategy - accelerating early drug development with clinical trials in Australia
Organiser: Australian Trade and Investment Commission, Australian Embassy
Opening ：Why Australia for Clinical Trials
Leo Bremanis
Trade and Investment Commissioner, Australian Embassy
Presenter 1 First in Human Sites in Australia
Charles Beasley
Senior Business Development Manager. Veritus Research
Presenter 2 Australia as Your Gateway:
Partnering with CRO for Faster Global Development
Takeshi Mori
Country Head, Japan, Novotech
Presenter 3 Manufacturing Capabilities in Australia
Ryan Parlette
Head of Commercial Operation, ENTRI
Presenter 4 How to take advantage of R&D Tax Incentives in Australia
Kenny Chen
Business Development Manager, Acclime
Panel discussion
Moderator: Mr. Takeshi Mori
Panellists: Team Australia delegation members
|
|
| Formulation Development Seminar |
| Preparation Development Seminar【Seminar Room C5】 |
| C5-06 |
21 April (Tue.) |
15:30
|
16:15 |
Next-Generation Manufacturing Solutions for Regenerative Medicines: From Lab Scale to Commercial Success
Mr. Julian Grossmann
Sales Manager
Advanced Therapies
Harro Höfliger
|
|
